Company Overview

Anteris Technologies Global Corp. is a structural heart medical technology company focused on developing next-generation transcatheter heart valve therapies for the treatment of aortic stenosis and related cardiovascular disease. The company’s primary commercial and development activities center on its proprietary transcatheter aortic valve replacement (TAVR) platform, including the DurAVR® transcatheter heart valve system and related biomaterial technologies. Anteris operates within the cardiovascular medical device and biotechnology industries, targeting interventional cardiologists, cardiac surgeons, and healthcare systems involved in structural heart procedures.

The company evolved from earlier biomaterials and regenerative medicine operations before shifting strategic emphasis toward structural heart technologies and minimally invasive valve replacement systems. Its positioning is tied to proprietary tissue engineering capabilities and anti-calcification technologies designed to improve valve durability and hemodynamic performance. Revenue historically has included biomaterials-related activities and research collaborations, though the company’s strategic focus has increasingly centered on advancing clinical development, regulatory pathways, and commercialization opportunities for the DurAVR® platform.

Business Operations

Anteris conducts operations through its structural heart technology and biomaterials development activities, with the DurAVR® TAVR system representing the company’s principal development-stage asset. The company utilizes proprietary ADAPT® anti-calcification tissue processing technology intended to improve tissue durability and biocompatibility in cardiovascular implants. Core activities include clinical development, device engineering, regulatory submissions, intellectual property management, manufacturing process development, and physician training associated with transcatheter valve therapies.

Operations span research, manufacturing support, and clinical engagement activities across multiple jurisdictions. The company maintains relationships with clinical investigators, hospitals, and cardiovascular specialists participating in valve studies and procedural evaluations. Anteris also controls intellectual property associated with tissue processing and heart valve design technologies. Public disclosures indicate the company has engaged external manufacturing, clinical, and regulatory partners to support product development and commercialization initiatives. Data regarding certain partnership economics and operational arrangements remains limited in publicly available disclosures.

Strategic Position & Investments

Anteris has positioned itself as a specialized structural heart innovator focused on improving long-term valve durability and physiologic performance in TAVR procedures. Strategic priorities include advancing clinical trials for the DurAVR® system, expanding physician adoption through procedural evaluations, pursuing regulatory clearances in major healthcare markets, and strengthening manufacturing readiness. The company has invested substantially in device engineering, clinical evidence generation, and intellectual property related to valve design and biomaterial processing.

The company’s growth strategy has emphasized internal technology development rather than large-scale diversification. Its principal strategic asset remains the DurAVR® platform supported by the ADAPT® tissue technology portfolio. Anteris has also pursued expansion of clinical and operational capabilities in the United States to align with the large and growing structural heart market. Public filings and investor communications indicate continued investment in regulatory preparation, product validation, and commercialization infrastructure associated with transcatheter valve therapies.

Geographic Footprint

Anteris maintains an international operational footprint with activities spanning the United States, Australia, and additional global healthcare markets connected to clinical development and cardiovascular device research. The company has historically maintained corporate and operational ties to Australia while increasingly emphasizing the U.S. market due to its importance in structural heart procedures, physician adoption, and regulatory opportunity.

Its clinical and strategic activities extend into multiple regions through investigator relationships, product evaluations, and intellectual property protections. The company’s technologies are designed for global structural heart markets where aging populations and increasing prevalence of aortic stenosis are driving demand for minimally invasive valve replacement procedures. Public disclosures indicate the company continues to prioritize expansion of its presence in key cardiovascular treatment centers internationally.

Leadership & Governance

Anteris’ leadership team is focused on advancing structural heart innovation, clinical validation, and regulatory execution in the competitive TAVR market. The company’s governance approach emphasizes medical technology development, physician engagement, and long-term value creation through proprietary cardiovascular technologies. Leadership communications have consistently highlighted product differentiation through valve durability, biomaterial science, and hemodynamic performance.

Key executives and leadership figures have included:

• Wayne Paterson – Chief Executive Officer
• John Seaberg – Chief Financial Officer
• Christopher Meduri, MD – Chief Medical Officer
• Morteza Naghavi, MD – Senior medical and scientific leadership roles associated with structural heart development

Executive composition and titles may change over time based on corporate filings and governance updates. Certain leadership appointments and role transitions may vary across reporting periods. Data inconclusive based on available public sources for any unconfirmed or recently updated executive changes.